Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent recombinant human papillomavirus vaccine (types 6, 11, 16, 18) (Hansenula polymorpha)
- Development stage
- Unknown
- Lead developer
- Sinopharm
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a quadrivalent recombinant vaccine designed to protect against human papillomavirus (HPV) types 6, 11, 16, and 18. Developed by the Chengdu Institute of Biological Products (a subsidiary of China National Biotec Group / Sinopharm), the vaccine utilizes the *Hansenula polymorpha* (Pichia angusta) yeast expression system to produce virus-like particles (VLPs) of the L1 capsid protein. This methylotrophic yeast system is chosen for its high-yield production capabilities and ability to perform complex post-translational modifications. The vaccine is intended for the prevention of cervical cancer, vulvar and vaginal cancers, and genital warts caused by the targeted HPV types in both females and males. It is currently in late-stage clinical development in China, following successful safety and immunogenicity studies in various age groups.
- Other names
- quadrivalent recombinant human papillomavirus vaccine (types 6, 11, 16, 18) (Hansenula polymorpha)Chengdu HPV4 vaccineCDIBP HPV4
02
Targets
HPV18 L1HPV11 L1Human papillomavirus type 16 L1 capsid proteinHPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on quadrivalent recombinant human papillomavirus vaccine (types 6, 11, 16, 18) (Hansenula polymorpha).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent recombinant human papillomavirus vaccine (types 6, 11, 16, 18) (Hansenula polymorpha).